Cervical Cancer Survival Influenced by Presence of Diabetes Mellitus
the Cancer Therapy Advisor take:
Diabetes mellitus (DM) was determined to be an independent unfavorable prognostic factor in Asian patients with early cervical cancer (CC), according to an article published online in the journal The Oncologist.
In this study, 2,946 patients diagnosed with primary stage 2-2A CC and received curative treatments between 2004 and 2008 were identified from the nationwide Taiwan Cancer Registry database. In total, 284 (9.6%) patients had DM.
Results showed patients with DM had significantly lower 5-year cervical cancer-specific survival (CSS) and overall survival (OS) rates compared to patients without DM (CSS: 85.4% vs. 91.5%; OS: 73.9% vs. 87.9%, respectively).
The investigators found that DM remained an independent unfavorable prognostic factor for CSS (aHR, 1.46) and OS (aHR, 1.55), after adjusting for clinicopathologic variables and comorbidities.
The study’s findings indicated that the risk of cancer recurrence and death in patients with early stage CC may be increased by DM, even after receiving curative treatments.
Diabetes mellitus determined to be an independent unfavorable prognostic factor in Asian patients with early cervical cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer